The structural profiles are close, with argenx SE carrying a narrow edge on growth. Alnylam Pharmaceuticals still has the edge on growth, which keeps the comparison from looking entirely one-sided. On the market side, argenx SE is in better shape — its trend is intact while Alnylam Pharmaceuticals's trend has broken down. That puts structure and market broadly in agreement — argenx SE's lead looks more confirmed than conflicted.
The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (ALNY: Russell 1000, ARGX.BR: STOXX 600).
Growth points more clearly toward Alnylam Pharmaceuticals, Inc., even if the broader score still leans toward argenx SE.
Both operate in: Biotechnology
This comparison is based on industry proximity, not on functional trajectory similarity. ALNY and ARGX.BR share the same industry classification.
For a similarity-based comparison, see how Alnylam Pharmaceuticals and argenx SE each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The clearest separation appears in growth.
Left means cheaper relative valuation. Higher means stronger structure.
Structure stays fairly close here, while current pricing still looks more supportive for argenx SE.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where ALNY and ARGX.BR each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
The current lead is backed by a stronger multi-year growth trajectory.
Alnylam Pharmaceuticals, Inc. still shows lower market-fundamental divergence, which keeps the wider picture mixed rather than completely one-sided.
Growth is the clearest driver of the lead, with valuation adding further support — though growth still provides a real counterweight.
Break down the ALNY vs ARGX.BR comparison across all dimensions with the full interactive tool.
Explore how ALNY and ARGX.BR each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.